Bronco Amoxidin

Quick links

Choose a section

Quick links to important sections

Advertisements

Bronco Amoxidin

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Bronco Amoxidin

What is Bronco Amoxidin?

Bronco Amoxidin is a combination pharmaceutical product formulated to address respiratory conditions involving bacterial infection and excessive mucus production. It typically consists of two primary active components: amoxicillin and ambroxol.

Active Components

  • Amoxicillin: This is a broad-spectrum antibiotic belonging to the penicillin group. It works by interfering with the synthesis of bacterial cell walls, which leads to the elimination of susceptible bacteria.
  • Ambroxol: This is a mucolytic agent. Its primary function is to thin and loosen mucus in the airways, making it easier to expel through coughing. It also assists in improving the transport of secretions.

Mechanism of Action

The combination is designed to provide a dual approach to respiratory ailments. While the antibiotic component targets the underlying bacterial cause of an infection, the mucolytic component addresses the symptoms of congestion. By reducing the viscosity of bronchial secretions, the medication helps clear the respiratory tract, which may also facilitate the penetration of the antibiotic into the lung tissue.

Common Applications

This medication is generally used for infections of the lower and upper respiratory tract where thick mucus is present, such as:

  • Acute and chronic bronchitis
  • Bacterial pneumonia
  • Bronchiectasis
  • Inflammatory conditions of the sinuses or middle ear when complicated by bacterial infection

Because it contains an antibiotic, this medication is only effective against infections caused by bacteria and will not be effective for viral illnesses like the common cold or flu.

Advertisements

What side effects are possible with Bronco Amoxidin?

Possible side effects and safety information

Adverse Reactions Summary

Classification Adverse Reactions (by System-Organ Class)
Common (Greater than 1%) Diarrhea, rash, nausea, vomiting
Serious / Clinically Significant Severe hypersensitivity (anaphylaxis), Severe Cutaneous Adverse Reactions (SCARs - including Stevens-Johnson syndrome, Toxic Epidermal Necrolysis), Clostridioides difficile-associated diarrhea (CDAD), Drug-Induced Enterocolitis Syndrome (DIES), Hepatic dysfunction (cholestatic jaundice, acute liver failure), Convulsions, Aseptic Meningitis, Hemolytic Anemia, Interstitial Nephritis, Crystalluria

The most frequently reported adverse events in clinical trials were diarrhea, rash, vomiting, and nausea. Many adverse reactions are classified as common, but some, such as serious allergic and skin reactions, are rare yet potentially fatal.

Safety Restrictions and Monitoring

Bronco Amoxidin is contraindicated in patients with a history of serious hypersensitivity to penicillins or other beta-lactam antibiotics. Patients with suspected or confirmed infectious mononucleosis should not receive this medication due to the high risk of developing a non-allergic rash.

Discontinuation is required if an allergic reaction, a severe cutaneous reaction (SCARs), or Drug-Induced Enterocolitis Syndrome (DIES) occurs. Prolonged use may result in the development of superinfections with non-susceptible organisms. Caution and potential dose adjustment are necessary for patients with renal impairment, particularly severe impairment. The medication may also reduce the effectiveness of oral contraceptives.

All patients must be evaluated for CDAD if diarrhea occurs during or up to two months after cessation of therapy, as this complication can range from mild to life-threatening colitis. Monitoring is advised in patients with existing hepatic impairment.

Advertisements

Overdose and Emergency Response

The official regulatory profile for Bronco Amoxidin (Amoxicillin) overdose is defined by the potential for severe systemic disturbances, primarily involving the renal, gastrointestinal, and central nervous systems.

Overdose presentations documented in regulatory sources include significant gastrointestinal distress such as nausea, vomiting, and diarrhea. More serious clinical manifestations may affect the central nervous system, potentially leading to confusion, agitation, reversible hyperactivity, and convulsions (seizures).

A major documented risk is the development of crystalluria—the formation of drug crystals in the urine—which may result in acute renal impairment. This risk is notably higher in individuals with pre-existing severe renal impairment, with signs including decreased or bloody urine.

In the event of a suspected overdose, the initial mandated action is the discontinuation of therapy and immediate contact with a Poison Control center. Urgent medical attention is required if life-threatening symptoms are observed, such as collapse, a seizure, or trouble breathing. As no specific antidote is known, treatment is supportive and symptomatic, with adequate fluid intake required to mitigate the risk of crystalluria. Regulatory documents also mandate specific laboratory follow-up to monitor the body's response.

Advertisements

Therapeutic Uses of Bronco Amoxidin

What Bronco Amoxidin Treats: Main Uses and Benefits

The primary therapeutic benefit of Bronco Amoxidin is that it plays a role in managing the susceptible bacterial pathogen across multiple bodily systems. This approach assists in addressing the cause of symptomatic discomfort and supports the patient during difficult episodes by easing distress. This medication is used to manage infections caused by bacteria, and may not assist with viral illnesses such as the common cold or flu.


Key Therapeutic Domains and Patient Benefit

This medicine is commonly used across conditions presenting with systemic or localized discomfort, particularly in the respiratory, genitourinary, and integumentary systems. It is considered relevant for easing distress in common infections, including acute otitis media, bacterial sinusitis, tonsillitis, pneumonia, and UTIs. When symptom clusters may become intense or disruptive and interfere with daily comfort—such as fever, intense localized pain, or painful urination—the drug provides support that helps ease the overall symptom burden.

“This medicine is applied in contexts where additional symptomatic support is needed to help patients cope more steadily with difficult episodes.”

It is also applied in specific clinical settings, such as managing the Helicobacter pylori bacterium associated with stomach ulcers and for prophylactic purposes before certain medical procedures.


Quick Facts and Indications

Quick Fact: Relief for Acute Symptoms Description
Symptom Axes Targeted Symptoms related to inflammatory or irritative states; symptoms related to systemic imbalance (fever); symptoms that create noticeable physiological strain (painful urination, persistent cough).
Main Indication Listing Commonly used for ear infections, sinus infections, strep throat, bronchitis, pneumonia, UTIs, and dental abscesses.
Clinical Context Commonly used when short-term symptomatic assistance is needed during acute episodes.
Patient Benefit Contributes to improved day-to-day comfort and assists with maintaining functional stability during symptomatic phases.

Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

Eligibility and Contraindications

Official regulatory information outlines specific populations that must not use Bronco Amoxidin (Amoxicillin) and groups for whom use is restricted or requires special consideration.

Classification Population or Condition
Contraindicated Individuals with a history of a serious hypersensitivity reaction (e.g., anaphylaxis, Stevens-Johnson syndrome) to amoxicillin or to any other beta-lactam antibiotic (including penicillins and cephalosporins).
Use Not Recommended Patients with infectious mononucleosis (mononucleosis or "mono"). Use is cautioned against due to a high risk of developing a non-allergic skin rash.

Restricted Use and Special Populations

  • Severe Renal Impairment: Use is restricted and requires careful dose adjustment due to delayed drug elimination. The maximum dose is often reduced, and certain formulations (e.g., extended-release tablets) are contraindicated in patients with severe kidney impairment.
  • Pediatric Use: Neonates and infants three months of age and younger require a modified maximum daily dose due to incompletely developed renal function.
  • Phenylketonuria (PKU): Chewable tablet formulations containing phenylalanine are contraindicated for use in patients with Phenylketonuria.
  • Pregnancy and Lactation: Amoxicillin is categorized as Pregnancy Category B, indicating no evidence of harm in studies. It is excreted in human milk, and caution is advised during lactation as it may lead to infant sensitization.
Advertisements

What should I know about interactions with other medicines?

The official regulatory profile for Bronco Amoxidin documents specific interaction patterns concerning the drug's plasma concentration and its potential to alter the effects of co-administered medicines. All statements are based strictly on governmental product labeling.

Interactions Affecting Drug Exposure

A documented pharmacokinetic interaction occurs with Probenecid. This substance inhibits the renal tubular secretion of Amoxicillin, competitively interfering with its elimination. The consequence of this interference is a documented increase and prolongation of Amoxicillin blood plasma levels. A similar risk is noted with Methotrexate, where Amoxicillin may reduce its renal clearance, potentially leading to elevated exposure and a risk of Methotrexate toxicity.

Interactions Affecting Efficacy and Risk

Regulatory documents address pharmacodynamic changes when Bronco Amoxidin is co-administered with Oral Anticoagulants (such as Warfarin), noting a potential risk of prolongation of prothrombin time (INR). The official labeling also notes that this medicine may reduce the efficacy of combined Oral Contraceptives. Furthermore, the co-administration of Allopurinol is officially associated with an increased incidence of skin rash. The product's absorption is not significantly affected by food, meaning there is no mandatory administration-timing constraint relative to meals.

Advertisements

Mechanism of Action

Targeting Bacterial Cell Wall Synthesis

This medication's primary action is exerted within the peptidoglycan synthesis pathway of bacteria. It identifies and binds to penicillin-binding proteins (PBPs), which are bacterial enzymes critical for the final stages of cell wall synthesis. This specific enzyme-mediated signaling blocks the cross-linking of the cell wall structure.

Inducing Microbial Lysis and Death

By irreversibly binding to PBPs, Bronco Amoxidin initiates a specific molecular cascade that prevents the bacteria from completing or maintaining its structural integrity. This pathway interference leads to the activation of autolytic enzymes within the bacteria, causing the cell to lose its osmotic balance, rupture, and die (lysis). The outcome of this cascade is bacterial cell lysis and death.

Selective Action Profile

The drug's mechanism is highly selective, operating strictly within domains that involve bacterial enzyme systems. Because human cells do not possess a peptidoglycan cell wall or the associated PBPs, the drug does not engage the core regulatory pathways of the host. This selectivity ensures that the mechanism of action primarily involves microbial enzymes and does not engage the core regulatory pathways of the host.

Advertisements

Dosage and Administration Information

How to Use Bronco Amoxidin

Bronco Amoxidin is officially administered via the Oral route in various dosage forms, although preparations for Intravenous (IV) injection are approved for use in hospital settings. For adults, the standard oral dosing for most infections typically ranges from 250 mg to 875 mg, given on a divided schedule of every 8 hours or every 12 hours. Pediatric dosing for children over three months of age is determined based on body weight, with an upper limit of 30 mg/kg/day for infants aged three months or younger.


The medicine may generally be taken without regard to meals. However, certain high-dose or extended-release forms are officially directed to be taken with a light meal to meet labeling requirements. Regardless of the form, extended-release tablets must be swallowed whole and must not be crushed or chewed. For the oral suspension, the powder requires reconstitution with water and must be shaken well before each measured dose.


Treatment courses are defined by the infection type, with a minimum duration of 10 days required for infections caused by Streptococcus pyogenes to meet treatment guidelines. Dose adjustments are strictly mandated for adults with severe renal impairment (Glomerular Filtration Rate < 30 mL/min), often limiting the maximum daily intake. If a dose is missed, it is generally advised to take it as soon as remembered, but to skip the missed dose and resume the normal schedule if it is almost time for the next scheduled administration.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bronco Amoxidin


Evidence for Use in Pediatric Ear Infections (Acute Otitis Media)

The available research for Amoxicillin in ear infections (Acute Otitis Media, or AOM) includes Randomized Controlled Trials (RCTs). These short-term studies were conducted during periods of increased symptom activity, primarily exploring how symptoms change over time in infants and children up to 12 years of age. Researchers monitored clinical resolution (the reported change in symptoms) and measured the rates of treatment failure. Some studies compared outcomes for children receiving Amoxicillin versus children receiving a different intervention or observation. Findings describe patterns observed in the studies related to spontaneous resolution of symptoms. The research has explored whether outcomes were different in younger children or those with more severe initial symptoms. Long-term effects are not fully established regarding recurrence rates or hearing outcomes.

Evidence for Respiratory Infections, Including Pneumonia

Research examined a range of studies for respiratory conditions, including certain types of Community-Acquired Pneumonia (CAP) in both adults and children. Research designs include RCTs and systematic reviews. Studies explored outcomes related to functional imbalance and patient-reported outcomes describing perceived discomfort, such as the frequency of hospitalization or a change in therapy. These studies monitored clinical success versus clinical failure (the need to switch to a different treatment). Research describes the observed evolution of symptom patterns in these groups, often comparing the outcomes of Amoxicillin to those of other common anti-infective agents.

What is Still Uncertain in the Research Landscape

Several areas of uncertainty exist within the evidence base for Amoxicidin. One primary area of uncertainty relates to the optimal treatment duration, as the findings were mixed when comparing very short courses against longer, conventional courses for many infections. Furthermore, evidence is limited for specific subsets of patients, such as those with complex underlying health issues or certain comorbidities. Ultimately, comparative evidence is lacking for certain new or emerging bacterial strains, and research is ongoing to assess how local antibiotic resistance patterns may affect the measured outcomes.

Key Studies & References

  1. Revised WHO classification and treatment of childhood pneumonia at health facilities (WHO 2014 Policy Brief)
  2. 14-day pantoprazole- and amoxicillin-containing high-dose dual therapy for Helicobacter pylori eradication in elderly patients: A prospective, randomized controlled trial
  3. Acute Otitis Media: Low Dose Versus High Dose Amoxicillin (Clinical Evidence Review)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Bronco Amoxidin (FAQ)


Q: Are there any common foods or drinks that should be avoided with Bronco Amoxidin?

Official product information states there are no mandatory food restrictions for absorption, meaning the drug can generally be taken with or without food. However, some guidance suggests that avoiding high-fat or highly acidic foods may help prevent mild stomach upset. Taking the medicine with a light meal is often noted as a way to minimize gastrointestinal discomfort.

Q: Is Bronco Amoxidin safe for use in older adults (seniors)?

Regulatory documents describe the medication as generally acceptable for use in older adults, but note that dose adjustments may be necessary. This precaution is taken due to the higher likelihood of decreased kidney function in the elderly population, which can affect how the body processes the medicine.

Q: How is Bronco Amoxidin typically eliminated from the body?

According to official regulatory documents on pharmacokinetics (how the body handles the drug), the medication is primarily eliminated by the kidneys. A majority of the dose is excreted unchanged in the urine within 6 to 8 hours of administration.

Q: Is it true that taking Bronco Amoxidin with dairy products can affect how it works?

Regulatory summaries and patient information generally indicate that taking this medicine with dairy products is not a concern. The medication’s absorption is not significantly affected by dairy, unlike some other classes of antibiotics.

Q: How long does Bronco Amoxidin stay in your system after the last use?

In individuals with normal kidney function, the medicine has a short elimination half-life (the time it takes for half the drug to be cleared) of approximately one hour. Detectable levels are typically observed in the blood for up to 8 hours after an oral dose.

Q: Is it necessary to finish the entire supply of Bronco Amoxidin?

Official patient information consistently states the necessity of finishing the full prescribed course. Stopping the medication early increases the risk of the infection returning, and surviving bacteria may develop resistance, making them harder to treat in the future.

Q: How is the safety profile of Bronco Amoxidin characterized in regulatory documents?

Regulatory documents characterize the safety profile by listing common, generally mild gastrointestinal and skin reactions (such as diarrhea and rash). The documents also contain warnings for rare but serious adverse events, including severe hypersensitivity (anaphylaxis) and C. difficile-associated diarrhea.

Q: What are the typical indications listed by the FDA for Bronco Amoxidin?

The FDA-approved indications for this medication include the treatment of infections caused by susceptible bacteria. These typically involve infections of the ear, nose, throat, genitourinary tract, skin and skin structure, and lower respiratory tract infections.

Q: Why do some people say Bronco Amoxidin causes drowsiness?

While drowsiness is not usually listed as a common adverse reaction in official regulatory documents, related effects have been reported. For example, some patients have reported dizziness and difficulty sleeping during the course of treatment.

Q: Can Bronco Amoxidin affect my ability to drive or use machinery?

Although official documents do not list drowsiness as a common side effect, they advise caution due to the potential for side effects like dizziness. Individuals should know how the medicine affects them before driving or operating heavy machinery.

Q: How long after starting Bronco Amoxidin should I expect to feel an effect?

Studies and patient counseling information indicate that the medication starts working shortly after the first dose. However, patients typically report noticing an improvement in their symptoms within 24 to 72 hours (1 to 3 days).

Q: What happens if I stop taking Bronco Amoxidin before the expected duration?

Official warnings state that stopping the medication early increases the risk of the infection returning. Additionally, the surviving bacteria may develop resistance to the medicine, which could make subsequent infections harder to treat.

Q: Is there a generic version of Bronco Amoxidin available?

Yes, the active ingredient in this medicine, Amoxicillin, is widely available. According to the FDA’s drug approvals database, it is available as a generic drug from multiple manufacturers.

Q: Can Bronco Amoxidin cause changes in mood or behavior?

Significant changes in mood or behavior are not commonly reported with this medication. However, central nervous system (CNS) effects are listed as rare adverse reactions in regulatory documents.

Q: Is it normal to have a slight headache when starting Bronco Amoxidin?

According to regulatory documentation listing adverse reactions, headache is one of the commonly reported side effects. This is a pattern often observed at the beginning of the treatment course.

Q: Are there any known interactions between Bronco Amoxidin and common supplements like Vitamin C or Magnesium?

Regulatory summaries note that there are no specific vitamins that must be avoided. Common mineral supplements like Magnesium or Vitamin C are not generally considered a major concern for affecting drug absorption.

Q: Is there an official list of all the ingredients in Bronco Amoxidin?

Yes, official regulatory labeling, such as the FDA prescribing information, contains a complete list of all ingredients. This includes the active ingredient and all inactive ingredients used in the final marketed formulations (e.g., capsules or suspensions).

Q: What should be done if I experience a mild stomach upset while using Bronco Amoxidin?

Mild stomach upset, such as nausea or diarrhea, is common. Patient information notes that taking the medicine with a light meal and ensuring adequate hydration are supportive measures sometimes used for mild stomach upset.

Q: Can using Bronco Amoxidin affect the results of any lab tests?

Yes, regulatory documents note that this medication can cause false-positive results when testing for glucose (sugar) in the urine. This interference occurs when using certain non-enzymatic methods, such as Clinitest.

Q: How quickly does Bronco Amoxidin reach its highest level in the blood?

Regulatory information on pharmacokinetics indicates that after oral administration of the standard form, the medicine typically reaches its highest concentration in the blood (Cmax) within 1 to 2 hours.

Q: What is the half-life of Bronco Amoxidin?

The elimination half-life (the time it takes for half of the drug to be eliminated) is approximately 61.3 minutes, or about one hour, in individuals with normal kidney function.

Q: Can Bronco Amoxidin cause changes in blood sugar levels?

Official information does not contain warnings for direct changes to blood sugar levels, but the medication is documented to interfere with certain urine glucose tests in patients with diabetes, leading to a false-positive result.

Q: What is the difference between the capsule and the tablet forms of Bronco Amoxidin?

The official forms differ in their inactive ingredients, physical dimensions, and specific requirements for use. For instance, extended-release tablets are typically not crushed or chewed, while standard capsules are usually swallowed whole, according to labeling.

Q: Does Bronco Amoxidin cause sensitivity to sunlight?

Regulatory information does not typically list sensitivity to sunlight (photosensitivity) as a common or serious adverse reaction associated with this medication, unlike some other antibiotic classes.

Q: What is the likelihood of having a serious side effect from Bronco Amoxidin?

Serious side effects, such as severe allergic reactions (anaphylaxis) or severe skin reactions, are officially documented in regulatory information. These events are characterized as rare or very rare.

Q: Is Bronco Amoxidin known to cause insomnia or difficulty sleeping?

Difficulty sleeping, also known as insomnia, is listed in patient information as a possible side effect of the medication.

Q: Are there different brand names for the same medicine as Bronco Amoxidin?

Yes, the active ingredient Amoxicillin is commonly known and sold under numerous other brand names. The specific brand names used vary depending on the country and formulation.

Q: Is Bronco Amoxidin a commonly prescribed medicine?

Yes, the medication is widely recognized and prescribed globally. According to public health data and essential medicines lists, it is considered one of the most commonly used antibiotics in primary care settings worldwide.

Q: Does Bronco Amoxidin interact with alcohol, and if so, how is it described in official sources?

There is no explicit contraindication with alcohol documented in official sources. However, official patient counseling generally notes that avoiding alcohol may help minimize common side effects like nausea, vomiting, and diarrhea.

Q: Is it possible to become reliant on Bronco Amoxidin?

No, official documentation on the drug's action confirms it is an antibiotic that targets bacterial cell walls. This medication does not act on the central nervous system in a way that is associated with any known risk of dependence or addiction.

Q: Can Bronco Amoxidin be used for prevention or is it only for treatment?

While its primary purpose is treating active bacterial infections, the medicine is also documented in public health and dental guidelines for certain prophylactic (preventative) uses. This includes administration in at-risk patients prior to certain dental procedures.

Q: Does Bronco Amoxidin have a risk of causing stomach ulcers?

The medication is not explicitly associated with causing stomach ulcers in regulatory documents. However, official warnings do cover severe gastrointestinal issues like C. difficile-associated diarrhea (CDAD) and Drug-Induced Enterocolitis Syndrome (DIES).

Advertisements

How should Bronco Amoxidin be stored and disposed of?

Storage and Disposal Conditions for Amoxicillin

Storage Requirements

The required storage environment for Amoxicillin depends on its form. Capsules and dry powder for suspension must be stored at Controlled Room Temperature (typically 20 C to 25 C) in a tightly closed container and protected from excessive moisture.

The reconstituted (mixed) oral suspension must be stored in a refrigerator (2 C to 8 C) and must not be frozen. The refrigerated suspension must be discarded after 14 days. All medication must be kept out of the reach of children.

Disposal Instructions

Unused or expired Amoxicillin should be taken to an authorized drug take-back program. If a program is unavailable, follow the official non-flush method: mix the medicine with an undesirable substance, seal it in a container, and place it in the household trash. The medication should not be flushed down a toilet or poured down a sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bronco Amoxidin found in:

A-Z Index: